Acting Center for Drug Evaluation and Research Director Tracy Beth Høeg reportedly disagreed with staff who wanted to approve ...
Sarepta Therapeutics has put in place several initiatives to help its gene therapy Elevidys return to growth, but recovery ...
Gilead is laying off Arcellx employees in California and Maryland, with some cuts effective this year and the remainder ...
Pfizer-backed cancer company CellCentric will use the cash to support the launch of a pivotal myeloma trial testing its ...
The selloff in Eli Lilly's shares was “overdone,” according to RBC Capital Markets, which noted that the overall safety ...
Analysts and investors alike had been eagerly awaiting sales figures for Novo Nordisk’s Wegovy pill. The answer blew past ...
Robert F. Kennedy Jr.’s health department has consistently touted radical transparency as being key to its mission. Recent ...
Despite the continued decline of Pfizer's COVID-19 products, shares stayed stable on Tuesday morning after the New York ...
The action affects BioNTech sites in Germany and Singapore, where the company expects to have excess capacity.
Novel targets aim to stop lung scarring—where current drugs only slow it—while improving tolerability and unlocking fibrosis ...
Katherine Szarama, who has served as Prasad’s deputy at the Center for Biologics Evaluation and Research since December, joins a long list of temporary leaders at the Department of Health and Human ...
As Q1 earnings arrive, three biotechs have big quarters ahead, with two—Amylyx and Neumora Therapeutics—betting at least ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results